Hospital-Acquired Vancomycin-Resistant Enterococci: A Report of 2-year Ex-perience
-
Mehradad Hasibi
,
Jalal Rezaii
,
Babak Mohajer Iravani
,
Seyed Bahram Moslemi
,
Maziyar Rahimi Haji-Abadi
,
Seyed Morteza Taghavi
,
Mitra Haji-Nouri
Abstract
Vancomycin-resistant enterococci (VRE) are becoming a major concern in medical practice. Their increased prevalence and their ability to transfer vancomycin resistance to other bacteria have made them a subject of close scrutiny and intense investigation. Colonization is usually acquired by susceptible hosts in an environment with a high rate of patient colonization with VRE. The aim of this study was to define the prevalence and risk factors of infections with VRE in Amir-Alam Hospital (Tehran, Iran). Fecal samples of 422 newly admitted patients (Group A) and 93 patients with either at least 48-hours of hospitalization or chronic renal failure under hemodialysis (group B) were evaluated for VRE isolates by MIC method in microbiology laboratory in Pasteur Institute of Iran. Stool cultures were positive for enterococci in 310 (73.4 %) and 89 (95.7 %) patients in group A and B, respectively. The prevalence of VRE isolates was 1.42 % (6 patients from 422) in group A and 7.52 % (7 patients from 93) in group B by MIC method (P < 0.05). In group A, a significant relationship was found between the VRE colonization and underlying conditions like as history of hospitalization and surgery within previous year and antibiotic therapy within three months ago. Prevalence of VRE colonization is increasing in hospitals. Our results indicate the importance of underlying diseases as risk factors for VRE colonization.
Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases, United States, 1997. MMWR Morb Mortal Wkly Rep 1998;46(54):ii-vii, 3-87.
Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342(10):710-21.
Hayden MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis 2000;31(4):1058-65.
Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23(4):767-72.
Morris JG Jr, Shay DK, Hebden JN, McCarter RJ Jr, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123(4):250-9.
Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987;9(6):1065-78.
National Committee for Clinical Laboratory Standards(NCCLS). Performance Standards for Antimicrobial SusceptibilityTesting: Thirteenth International Supplement M100-S13, Table 2D. USA: NCCLS, Wayne, PA, 2003.
Uttley AH, Collins CH, Naidoo J, George RC. Vancomycinresistant enterococci. Lancet 1988;1(8575-6):57-8.
Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998;19(8):539-45.
Burrell LJ, Grabsch EA, Padiglione AA, Grayson ML. Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodialysis outpatients in Victoria:implications for screening. Med J Aust 2005;182(9):492.
Streit JM, Jones RN, Sader HS, Fritsche TR. Assessmentof pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24(2):111-8.
Bonten MJ, Slaughter S, Ambergen AW, Hayden MK, van Voorhis J, Nathan C, et al. Arch Intern Med 1998; 158(10):1127-32.
Patel R, Allen SL, Manahan JM, Wright AJ, Krom RA,Wiesner RH, et al. Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients.Liver Transpl 2001;7(1):27-31.
Perencevich EN, Fisman DN, Lipsitch M, Harris AD, MorrisJG Jr, Smith DL. Projected benefits of active surveillancefor vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004;38(8):1108-15.
Puzniak LA, Gillespie KN, Leet T, Kollef M, Mundy LM. A cost-benefit analysis of gown use in controlling vancomycin- resistant Enterococcus transmission: is it worth the price? Infect Control Hosp Epidemiol 2004;25(5):418-24.
Chavers LS, Moser SA, Benjamin WH, Banks SE, Steinhauer JR, Smith AM, et al. Vancomycin-resistant enterococci:
years and counting. J Hosp Infect 2003;53(3):159-71.
Orloff SL, Busch AM, Olyaei AJ, Corless CL, Benner KG, Flora KD, et al. Vancomycin-resistant Enterococcus in liver transplant patients. Am J Surg 1999;177(5):418-22.
Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002;35(10):1139-46.
Kapur D, Dorsky D, Feingold JM, Bona RD, Edwards RL, Aslanzadeh J, et al. Incidence and outcome of vancomycinresistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;25(2):147-52.
Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003;51 (Suppl 3):iii13-21.
| Files | ||
| Issue | Vol 47, No 6 (2009) | |
| Section | Articles | |
| Keywords | ||
| Vancomycin enterococci gastrointestinal risk factors | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
